Skip to content

Curemark Management

To develop breakthrough research and treatments, Curemark relies on the support of some of the strongest minds in the industry. Our management offers a wealth of experience from a medical, operational and biotechnological standpoint. This gives our company a unique position to excel at what we do.

 

DR. JOAN FALLON

Founder and CEO

DR. JOAN FALLON

Founder and CEO

Dr. Fallon began her research on Autism and related disorders over 20 years ago and founded Curemark as a platform to develop product candidates to address her findings. Dr. Fallon has both clinical expertise and academic experience—the former from running a private practice specializing in pediatric development, and the latter as an Assistant Professor of Natural Sciences and Mathematics at Yeshiva University.

Dr. Fallon has played an integral role in two very successful (and unprecedented) medical ventures. She was an Oxford Health Plans board member and helped achieve underwriting authority from New York State, for alternative and complementary medicine where none had yet existed. She also helped implement a cost-effective, interdisciplinary health plan for Oxford that increased the level of quality care for all children enrolled there. Dr. Fallon has written numerous scholarly articles, lectured around the world on developmental problems in the pediatric population and served on the Board of Directors of the ICA and Kentuckiana Children’s Center. She serves as a Senior Advisor to the Henry Crown Fellows at The Aspen Institute, as well as a Distinguished Fellow at the Athena Center for Leadership Studies at Barnard College/Columbia University. She is also a member of the Board of Trustees of Franklin & Marshall College. Dr. Fallon holds a B.A. degree from Franklin and Marshall College, a DC degree from Palmer University, and has completed the coursework for the MSc in clinical investigation from Harvard University’s joint program with Massachusetts General Hospital.

MATTHEW F. HEIL, PhD

Chief Scientific Officer

MATTHEW F. HEIL, PhD

Chief Scientific Officer

Dr. Matthew F. Heil has served as Curemark’s Chief Scientific Officer since 2008. Dr. Heil is responsible for the oversight and direction of all scientific programs as well as drug formulation and manufacturing.

While a member of the Faculty of Medicine at New York Medical College (NYMC), Dr. Heil became a Principal Investigator conducting research on growth regulation in leukemia. He also served on NYMC’s Experimental Bone Marrow Transplant Team investigating new methodologies for allowing bone marrow transplants for patients who did not have a matching graft donor.

As a Senior Partner of both the Delphi Group and BioInnovators Consulting, Dr. Heil worked closely with senior management teams at biotechnology and pharmaceutical companies on product licensing, product valuation, technical due diligence and other aspects of research and product development .

Dr. Heil holds a Bachelor of Science in Biology from Loyola University in Chicago, a Master’s Degree from the University of Toronto and a Doctorate in Immunology from Syracuse University.

WILLIAM MCINTYRE, PhD

SVP, Global Regulatory Affairs

WILLIAM MCINTYRE, PhD

SVP, Global Regulatory Affairs

William McIntyre, PhD, currently serves as the Senior Vice President of Global Regulatory Affairs at Curemark, a biotechnology company focused on unmet medical needs in neurology and psychiatry. William has dedicated his career to drug development and has held a variety of senior executive roles in Pharma.

William has over 30 years of experience in Regulatory Affairs and drug development. He has been responsible for pre- and post-approval activities supporting almost a dozen NDAs, multiple BLAs, dozens of INDs, and hundreds of ANDAs, as well as devices. To accomplish these filings, William has built and maintained productive Regulatory Affairs groups in US, Europe, Latam, and Asia.

William’s therapeutic exposure and interaction with FDA/global health authorities includes analgesics, anti-infective, antihistamines, anti-inflammatory, anti-fungal, anxiolytics, blood glucose regulators, cardiovascular agents, depression, dermatological agents, neurodevelopmental agents and immunological agents. Recently, William’s team gained the approval (July 6, 2020) of Qwo® (collagenase clostridium histolyticum-aaes), as a first in class therapeutic product. The Qwo® BLA was a 10-month, first pass approval.

In addition to his traditional Regulatory Affairs roles, William has also held cGMP compliance roles. He has hosted dozens of cGMP, pre-approval, post-approval, “for cause”, DEA, and pharmacovigilance health authority inspections in US, Europe, Latam and Asia. He has also been the final reviewer of the responses to these respective health authority compliance groups and negotiated compliance outcomes, including multiple consent decrees and facility rehabilitations.

His manufacturing background includes virtually all dosage forms and the development of manufacturing processes that span the range from small molecules to complex fermentation products. He has also overseen the construction of manufacturing facilities around the world including a new Biosafety Level 3 manufacturing site for Aplisol® (Tuberculin Purified Protein Derivative) in US, as well as facilities for sterile, and solid oral products around the globe.

William lives in the New York Hudson River Valley with his partner Renée and their two dogs; Rembrandt and Rebel. William’s son is a musician and resides in Brooklyn, NY.

STACY GRANT

SVP, Corporate Strategy & Finance

STACY GRANT

SVP, Corporate Strategy & Finance

Stacy E. Grant currently serves as the Senior Vice President of Corporate Strategy and Finance at Curemark a biotechnology company working on unmet medical needs in neurology and psychiatry. Ms. Grant served as a Managing Director at Morgan Stanley and enjoyed a successful 25-year career in finance and private wealth management. During her tenure, she advised some of the world’s largest and most influential entrepreneurs and companies, and collaborated on the launch of several top tier venture capital funds. A Finance Fellow at the Aspen Institute, Grant has helped many tech and biotech companies navigate the capital markets to fund their businesses at every stage of development and expansion. A recipient of numerous awards she has perennially been named a top 100 financial advisor in Barron’s and Forbes. Her deep insight into the financial markets has garnered the trust of founders, prominent CEOs and major investors globally.

SUZY JONES

SVP, Business Development

SUZY JONES

SVP, Business Development

Suzy Jones is the Founder and Managing Partner of DNA Ink, a life sciences advisory firm in San Francisco. Prior to founding DNA Ink, Ms. Jones spent 20 years at Genentech in various roles in immunology research, product development and business development where she was Head of Non-Oncology Licensing and later Interim Head of Partnering and Head of Business Development. During this time, she managed Genentech’s CD20 portfolio of assets, including Rituxan, the first monoclonal antibody launched to treat cancer, Ocrevus and Gazyva. Ms. Jones served as a member of the board of directors of Calithera Biosciences (formerly NASDAQ listed) and Patrys Limited, (ASX listed) Australian. She received a B.A. in Biology from University of California, Santa Cruz.

DEIDRE RONIGER

SVP, Commercial

DEIDRE RONIGER

SVP, Commercial

A business leader in biotech for 25 years, Deidre Roniger has a successful track record of bringing clarity to complex situations, understanding risk, and driving quality decisions across company stages from PC to commercialization, and therapeutic areas. She is known for her strong strategic agility, adaptability, and problem solving in various settings of company maturity from large Biopharma to startups. Experience includes P&L leadership, people management, culture change, developing long range plans and financing strategies, fundraising, and pre-launch planning.

Previously, Deidre served as SVP Corporate Development at Ambys Medicine a cell therapy start-up and was a Managing Partner at DNA Ink, a boutique life sciences consulting firm offering corporate strategy and transaction services for C-suite clients in biotech, medtech and pharma. She developed organic and inorganic growth strategies across the client base and participated in licensing efforts on multiple deals. Her previous experience includes nearly a decade at Genentech, where she held operational and leadership roles of increasing responsibility across the commercial organization. Throughout her career at Genentech, Deidre had P&L responsibility for a $250 million franchise for which she led the turn-around effort, managed a cost center of $75 million and was accountable for the accurate forecasting and analytical support of Genentech’s full portfolio of products and in-licensing opportunities. She led the Market Analysis & Strategy group at Genentech, overseeing over 110 FTEs, and was accountable for all analytical support.

Deidre earned an MBA from Wake Forest University and holds a BS in Biochemistry from the UC San Diego. In 2007, she was named Healthcare Business Women’s Association Rising Star. Selected for and completed Executive Women in Bio Boardroom Ready Program 2020.